NGM Biopharmaceuticals Inc (DELISTED) (NGM:DL)
1.54
0.00 (0.00%)
USD |
NASDAQ |
Apr 05, 16:00
NGM Biopharmaceuticals Cash from Investing (TTM): 114.29M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 114.29M |
| September 30, 2023 | 88.78M |
| June 30, 2023 | 97.37M |
| March 31, 2023 | 56.82M |
| December 31, 2022 | 14.32M |
| September 30, 2022 | 34.56M |
| June 30, 2022 | 51.41M |
| March 31, 2022 | 38.65M |
| December 31, 2021 | -71.65M |
| September 30, 2021 | -208.11M |
| June 30, 2021 | -231.87M |
| Date | Value |
|---|---|
| March 31, 2021 | -195.03M |
| December 31, 2020 | -51.00M |
| September 30, 2020 | 17.14M |
| June 30, 2020 | 32.22M |
| March 31, 2020 | 73.10M |
| December 31, 2019 | 48.72M |
| September 30, 2019 | 98.60M |
| June 30, 2019 | 68.20M |
| March 31, 2019 | 10.65M |
| December 31, 2018 | 38.73M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-231.87M
Minimum
Jun 2021
114.29M
Maximum
Dec 2023
4.028M
Average
38.65M
Median
Mar 2022
Cash from Investing (TTM) Benchmarks
| Catalent Inc | -374.00M |
| AIM ImmunoTech Inc | -0.832M |
| Perspective Therapeutics Inc | -48.19M |
| Protalix BioTherapeutics Inc | -22.05M |
| Armata Pharmaceuticals Inc | -6.374M |